TUCSON, AZ--(Marketwired - Aug 18, 2014) - CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced the expansion of its technical development team with the appointment of John Coates, Ph.D. as Technical Director for Spectroscopy Products.
A globally recognized spectroscopist and instrumentation expert with 40-years' experience in the fields of applied spectroscopy and analytical method development, Dr. Coates is charged with guiding the ongoing development of CDEX's spectral management systems for medication analysis and validation, with specific focus on achieving optimal performance of the ValiMed™ Medical Validation System product line. ValiMed solutions rely on a unique combination of specialized spectroscopic measurement techniques -- including Raman, UV absorption and molecular fluorescence -- to accurately analyze, identify and determine the concentration of a drug/dose within seconds.
Commenting on Dr. Coates' appointment, Dr. Wade Poteet, Chief Scientist at CDEX, noted, "We feel very privileged to have John joining our development team and fully expect that he will play an invaluable role in helping CDEX to further enhance the powerful capabilities of our current and future generations of ValiMed devices, particularly as we persist in our efforts to identify and develop several new market applications of our patented technologies."
Over the past four decades, Dr. Coates has earned global distinction for his many accomplishments in spectroscopic measurements and instrumentation. In 2013, the industry coveted Williams-Wright Award was bestowed on him by the Coblentz Society honoring his extraordinary body of work in the field. From 1974 through 1996, Dr. Coates served several leading industrial instrument manufacturers; and in 1996, he formed Coates Consulting, LLC, a firm specializing in scientific and industrial instrumentation. Since that time, he has advised client companies on the design and development of more than 75 unique instrument systems.
Dr. Coates graduated from Royal Windsor Grammar School for Boys, Windsor, Berkshire, England in 1964. He opted not to go directly to university in favor of beginning a career in Analytical Chemistry, working in the Castrol Lubricants Research Laboratories in Bracknell, Berkshire. Dr. Coates obtained his undergraduate degree as a GradRIC (Graduate of the Royal Institute of Chemistry, now the Royal Society of Chemistry) in 1971 while continuing to work as an Analytical Methods Development Chemist at Castrol (then Burmah-Castrol). Additional specializations included Industrial Administration (Business and Management) and Graphic/Classical Art (1969-1972). He began pursuing his Ph.D. in Analytical Chemistry in 1972 at Brunel University, West London, England. He started his thesis while working at Burmah-Castrol, Bracknell and also at the Burmah Research Laboratories, Bromborough, Cheshire. His thesis topic was the Analytical Chemistry of Synthetic Gas Turbine Engine Oils as applied to high performance jet engines (Olympus engines used in the Concorde Jet Airliner). Dr. Coates earned his Ph.D. 16 years later while working at Nicolet Instrument Corporation in the United States. His professionally awarded degrees and qualifications include Chartered Chemist (CChem) (similar to a certified professional), Chartered Scientist (CSci) and Fellow of the Royal Society of Chemistry (FRSC).
About CDEX Inc.
Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. The Company's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification; and include the ValiMed™ Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2™ product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com.
This news release may contain forward-looking statements. Forward-looking statements are indicated by words such as "expects," "intends," "anticipates," "believes," "forecasts," "plans" and similar expressions. These forward looking statements are based on our current expectations and actual results could differ materially. Our ability to achieve the results anticipated in such forward-looking statements is subject to risks and uncertainties, including, without limitation, our ability to successfully centralize and consolidate various support functions, operating results, market acceptance of our solutions, strong brand recognition and other risks detailed from time to time in our reports filed with the Securities and Exchange Commission. These forward-looking statements are made in accordance with "safe harbor" provided by the Private Securities Litigation Reform Act of 1995 and no assurance can be given that the future results that are the subject of such forward-looking statements will be achieved. The Company undertakes no obligation to publicly update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.